Amy E. Axel
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- CAR-T cell therapy research
Papers in
- Hematology 15
- Multiple Myeloma Research and Treatments 13
- Genetics 8
- Chronic Lymphocytic Leukemia Research 7
- Co-authors
- Amy Kate Sasser (13 shared papers)Brett M. Hall (7 shared papers)Nicholas J. Sullivan (3 shared papers)Venu Raman (1 shared paper)Farhad Vesuna (1 shared paper)Tatiana M. Oberyszyn (1 shared paper)Nilsa C. Ramirez (1 shared paper)Niels W.C.J. van de Donk (8 shared papers)
- Journals
- Blood (10 papers)Clinical Chemistry and Laboratory Medicine (CCLM) (3 papers)Blood Advances (2 papers)Clinical Cancer Research (2 papers)Leukemia (1 paper)
- Partner nations
- United StatesNetherlandsBelgium
In The Last Decade
Amy E. Axel
25 papers receiving 2.6k citations
Amy E. Axel's Hit Papers
Peers
Comparison fields: 5 of 89
- Hematology 1.1k
- Oncology 1.4k
- Genetics 319
- Physiology 123
- Immunology 546
Countries citing papers authored by Amy E. Axel
This map shows the geographic impact of Amy E. Axel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. Axel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. Axel more than expected).
Fields of papers citing papers by Amy E. Axel
This network shows the impact of papers produced by Amy E. Axel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. Axel. The network helps show where Amy E. Axel may publish in the future.
Co-authors
The 25 scholars most cited alongside Amy E. Axel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells Hit paper breakdown → | 2009 | 639 |
| 2 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Hit paper breakdown → | 2016 | 359 |
| 3 | 2016 | 324 | |
| 4 | 2007 | 198 | |
| 5 | 2017 | 198 | |
| 6 | 2021 | 148 | |
| 7 | 2007 | 107 | |
| 8 | 2016 | 105 | |
| 9 | 2018 | 105 | |
| 10 | 2020 | 99 | |
| 11 | 2020 | 79 | |
| 12 | 2016 | 75 | |
| 13 | 2012 | 54 | |
| 14 | 2009 | 39 | |
| 15 | 2016 | 38 | |
| 16 | 2016 | 24 | |
| 17 | 2015 | 17 | |
| 18 | 2016 | 15 | |
| 19 | 2017 | 12 | |
| 20 | 2014 | 8 |
About Amy E. Axel
Amy E. Axel is a scholar working on Hematology, Genetics, Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 27 papers that have together received 2.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (13 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Cancer Cells and Metastasis (4 papers), CAR-T cell therapy research (4 papers), Protein Degradation and Inhibitors (4 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (1.4k citations), Genetics (319 citations), Physiology (123 citations) and Immunology (546 citations). Amy E. Axel has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include Amy Kate Sasser, Brett M. Hall, Nicholas J. Sullivan, Venu Raman, Farhad Vesuna, Tatiana M. Oberyszyn, Nilsa C. Ramirez, Niels W.C.J. van de Donk, Henk M. Lokhorst and Tahamtan Ahmadi. Their work appears in journals such as Blood, Clinical Chemistry and Laboratory Medicine (CCLM), Blood Advances, Clinical Cancer Research and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.